The global Ivermectin Tablets market size is predicted to grow from US$ 553 million in 2025 to US$ 701 million in 2032; it is expected to grow at a CAGR of 3.5% from 2026 to 2032.

Ivermectin is used to treat river blindness (onchocerciasis), intestinal infection from threadworms (strongyloidiasis), and other kinds of worm infections. Ivermectin is an anthelmintic. It works by interfering with the nerve and muscle functions of worms, by paralyzing and killing them.

Global ivermectin tablet production is projected to reach 1.13 billion tablets by 2025, with an average price of US$0.50 per tablet. Gross profit margins typically range from 25% to 40%.

The upstream of the ivermectin tablet industry chain mainly includes the fermentation and chemical synthesis of the active pharmaceutical ingredient (API) ivermectin, excipients, and pharmaceutical packaging materials. Among these, the cost and quality consistency of the API have the greatest impact on the price and compliance of the finished product. The downstream is the core of the demand side, with applications concentrated in the prevention and treatment of human parasitic diseases, including common parasitic diseases such as intestinal nematode infections, scabies, and head lice. The main usage scenarios are hospitals, primary healthcare institutions, pharmacies, and public health projects. In developing countries and tropical regions, this product is widely included in government or international organization-led disease control programs, characterized by large-scale centralized procurement and long-term stable usage. Downstream users are highly price-sensitive but have strict requirements for supply stability and quality standards. In some mature markets, ivermectin is more often used as a prescription drug or for specific indications, with relatively stable demand but limited growth.

The overall industry development trend is characterized by a differentiated demand structure. Public health and centralized procurement channels maintain large-volume, low-price supply, while retail and hospital sectors focus more on dosage accuracy and compliant labeling. Key driving factors include the long-term presence of parasitic diseases in some regions, the continued advancement of public health prevention and control projects, and improved accessibility of generic drugs. The main obstacles are: patents having expired long ago leading to severe homogenization; intense price competition; stricter regulations on ivermectins indications in some markets; and public opinion and controversies surrounding its use outside of indications causing fluctuations in demand expectations.

Infinity Market Research newest research report, the Ivermectin Tablets Industry Forecast looks at past sales and reviews total world Ivermectin Tablets sales in 2025, providing a comprehensive analysis by region and market sector of projected Ivermectin Tablets sales for 2026 through 2032. With Ivermectin Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ivermectin Tablets industry.

This Insight Report provides a comprehensive analysis of the global Ivermectin Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ivermectin Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Ivermectin Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ivermectin Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ivermectin Tablets.

This report presents a comprehensive overview, market shares, and growth opportunities of Ivermectin Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    0.2mg
    0.5mg
    1mg
    2mg
    3mg
    6mg
    12mg
    Segmentation by Dosage Form:
    Plain Tablets
    Dispersible Tablets
    Chewable Tablets
    Enteric-Coated Tablets
    Sustained-Release Tablets
    Coated Tablets
    Segmentation by Purity:
    More than 99%
    98%-99%
    95%-98%

Segmentation by Application:

    Livestock
    Poultry
    Pets
    Wild Animals

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Merck (MSD)
    Teva
    Orion
    Substipharm
    Medical Valley Invest
    Galenicum Derma
    Centrafarm
    Laboratorios Liconsa
    Vygoris
    Exeltis
    Zydus UK
    Dr. Reddys Laboratories
    Edenbridge Pharmaceuticals
    Advagen Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Ivermectin Tablets market?
What factors are driving Ivermectin Tablets market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ivermectin Tablets market opportunities vary by end market size?
How does Ivermectin Tablets break out by Type, by Application?